Triple-negative breast cancer has a poor outcome compared with other breast cancer subgroups, and chemotherapy is the primary treatment for this disease. 'Omics' technologies have revealed high levels of heterogeneity and helped to identify potentially actionable molecular features in some triple-negative breast cancer subtypes. Proof-of-principle studies suggest a potential benefit from immunotherapy in patients with this disease. Herein, Bianchini et al. discuss the most promising therapeutic opportunities for triple-negative breast cancer.
- Giampaolo Bianchini
- Justin M. Balko
- Luca Gianni